Beecham's Augmentin launch
McKesson's PDS market data subsidiary reports that U.S. retail sales of the oral amoxicillin combo "are already approaching $500,000 (at acquisition cost) per week and are expected to increase significantly as the cold season approaches." PDS estimates Beecham has carved out 5% of retail amoxicillin market in "slightly over five weeks"
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.